Records containing: Uveal Melanoma
This is the wording recorded or indexed by the source. An agency index term is not necessarily an authorised indication. Co-listed drug names are not linked to this term as a treatment relationship.
Follow recorded terms in Drug Alerts for Android. Free includes unlimited local condition follows and an on-open recent-record watchlist. Plus adds no ads and personal organization tools.
All
FDA submission records
EMA medicine records
ClinicalTrials.gov record updates
ClinicalTrials.gov records with results posted
-
CLINICAL_TRIALS study record update · 2024-02-29Uveal Melanoma In Sonography and Color Fundus Photos - A Comparative Study
-
CLINICAL_TRIALS study record update · 2024-02-01A Phase 1B/2 Open-Label, Ascending Single and Repeat Dose Clinical Trial Designed to Evaluate the Safety and Efficacy of Light-activated AU-011 for the Treatment of Subjects With Small Primary Choroidal Melanoma
-
CLINICAL_TRIALS study record update · 2024-01-19Pilot Trial of Olaparib in Patients With Unresectable or Metastatic Melanoma With Mutations in BRCA1/2 Genes
-
CLINICAL_TRIALS study record update · 2023-12-06Phase II Trial of Adjuvant Crizotinib in High-Risk Uveal Melanoma Following Definitive Therapy
-
CLINICAL_TRIALS study record update · 2023-11-22Phase 1B/2 Study of PAC-1 and Entrectinib for Patients With Metastatic Uveal Melanoma
- Organize your saved records without ads with Plus.
-
CLINICAL_TRIALS study record update · 2023-10-10Patient Experience and Quality of Life During the Surveillance Phase of Uveal Melanoma: A Prospective Multi-method Study
-
CLINICAL_TRIALS study record update · 2023-10-05A Phase 1/2 Dose-Finding Study to Evaluate the Safety, Feasibility, and Activity of BPX-701, a Controllable PRAME T-Cell Receptor Therapy, in HLA-A2+ Subjects With AML, Previously Treated MDS, or Metastatic Uveal Melanoma
-
CLINICAL_TRIALS study record update · 2023-09-15A Phase II Trial of the PARP Inhibitor, Niraparib, in BAP1 and Other DNA Damage Response (DDR) Pathway Deficient Neoplasms (UF-STO-ETI-001)
-
CLINICAL_TRIALS study record update · 2023-08-31Multi-Center Phase Ib Study of Intermittent Dosing of the MEK Inhibitor, Selumetinib, in Patients With Advanced Uveal Melanoma Not Previously Treated With a MEK Inhibitor
-
CLINICAL_TRIALS study record update · 2023-08-15Phase Ib Trial of AEB071, a PKC Inhibitor, in Combination With BYL719, a PI3Kα Inhibitor, in Patients With Metastatic Uveal Melanoma
-
CLINICAL_TRIALS study record update · 2023-06-26Characterization of Vascular Response to Brachytherapy Using Functional Optical Coherence Tomography
-
CLINICAL_TRIALS study record update · 2023-06-18Morphological, Genetic and Tumour Microenvironment Characterisation in Uveal Melanoma and Impact on the Development of Metastasis and Mortality.
-
CLINICAL_TRIALS study record update · 2023-06-15Hepatic Arterial Infusion of Autologous Tumor Infiltrating Lymphocytes Preconditioned With Percutaneous Hepatic Perfusion With Melphalan in Patients With Melanoma and Liver Metastases
-
CLINICAL_TRIALS study record update · 2023-05-06An Open-Label Phase 1b Clinical Study of Intravenous CAVATAK® (Coxsackievirus A21, CVA21), in Combination With Ipilimumab in Subjects With Uveal Melanoma Metastatic to Liver (VLA-024 CLEVER)
-
CLINICAL_TRIALS study record update · 2023-05-06Retrospective Register for Uveal Melanoma
-
CLINICAL_TRIALS study record update · 2022-12-06A Phase II Study of Concurrent Stereotactic Body Radiotherapy With Relatlimab and Nivolumab in Patients With Metastatic Uveal Melanoma
-
CLINICAL_TRIALS study record update · 2022-10-03An Open-Label, Multicenter, Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7293583, A TYRP1-Targeting CD3 T-Cell Engager, in Participants With Metastatic Melanoma
-
CLINICAL_TRIALS study record update · 2022-09-29A Phase I, Multi-center, Open-label, Study of LXS196, an Oral Protein Kinase C Inhibitor, in Patients With Metastatic Uveal Melanoma
-
CLINICAL_TRIALS study record update · 2022-08-31Randomized Phase III Study Comparing an Adjuvant Chemotherapy With Fotemustin to Intensive Surveillance in Patients With High Risk Uveal Melanoma
-
CLINICAL_TRIALS study record update · 2022-07-25A Phase 1b Dose-escalation Study to Assess Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of PLX2853 in Subjects With Advanced Malignancies
-
CLINICAL_TRIALS study record update · 2022-05-16CLEAR Registry Study: An Open, 5-year Registry Study to Track Clinical Application of DecisionDx-UM Multigene Assay Results and Associated Patient Outcomes.
-
CLINICAL_TRIALS study record update · 2022-03-22Phase II Multicenter, Non Randomized, Open Label Trial of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated Metastatic Uveal Melanoma
-
CLINICAL_TRIALS study record update · 2022-01-21A Cohort IND Expanded Access Program (EAP) for Tebentafusp for Treatment of HLA-A*02:01 Positive Patients With Metastatic Uveal Melanoma
-
CLINICAL_TRIALS study record update · 2022-01-05The Role of Genetic Mutations and of Circulating mRNAs in Uveal Melanoma
-
CLINICAL_TRIALS study record update · 2021-12-28Observational Study of Genetic Predictors of Efficiency and Safety of Immune Checkpoints Inhibitors in Patients With Different Malignancies (ICIPRESIST-0519)